Erratum (DOI:10.1016/j.jacl.2007.07.004);Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia

Journal of Clinical Lipidology

Volumn 1, Issue 4, 2007, Pages 287-299

  Stein, Evan A ^a   Marais, A David ^b   Ducobu, Jean ^c   Farnier, Michel ^d   Gavish, Dov ^e   Hauner, Hans ^f   Kaplan, Andrew J ^g   Le Maulf, Florence ^h   Melezínková, Helena ^h  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Centre Hospitalier Universitaire de Tivoli   (Belgium)

^d Point Medical   (France)

^e WOLFSON MEDICAL CENTER   (Israel)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g Discovery Alliance Inc   (United States)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Dyslipidemia; Renal; Rosuvastatin; Safety; Simvastatin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; OPEN STUDY; PARALLEL DESIGN; PHARYNGITIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; URINALYSIS;

EID: 34548513542     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.09.002     Document Type: Erratum

References (39)

1. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 (2003) 152-160
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1601-1610
4. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
5. Middleton A., Binbrek A.S., Fonseca F.A., Wilpshaar W., Watkins C., and Strandberg T.E. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin 22 (2006) 1181-1191
6. McKenney J.M., Jones P.H., Adamczyk M.A., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 19 (2003) 689-698
7. Kritharides L. Reducing low-density lipoprotein cholesterol-treating to target and meeting new goals. Eur Heart J Suppl 6 suppl A (2004) A12-A18
8. Chadban S.J., Briganti E.M., Kerr P.G., et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 14 suppl 2 (2003) S131-S138
9. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
10. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here?. National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (1998) 853-906
11. K/DOQI Working Group. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39 (2002) S204-S212
12. Afzali B., Haydar A.A., Vinen K., and Goldsmith D.J. Beneficial effects of statins on the kidney: the evidence moves from mouse to man. Nephrol Dial Transplant 19 (2004) 1032-1036
13. Vidt D.G., Cressman M.D., Harris S., Pears J.S., and Hutchinson H.G. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102 (2004) 52-60
14. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
15. Bazzi C., Petrini C., Rizza V., Arrigo G., and D'Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 58 (2000) 1732-1741
16. Myers G.L., Cooper G.R., Winn C.L., and Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 9 (1989) 105-135
17. Warnick G.R., and Albers J.J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19 (1978) 65-76
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Steiner P.M., Freidel J., Bremner W.F., and Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL cholesterol with the lipid research clinics' methodology. J Clin Chem 19 (1981) 850-851
20. Johnson C.A., Levey A.S., Coresh J., Levin A., Lau J., and Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. Am Fam Physician 70 (2004) 1091-1097
21. Carroll M.F., and Temte J.L. Proteinuria in adults: a diagnostic approach. Am Fam Physician 62 (2000) 1333-1340
22. Simerville J.A., Maxted W.C., and Pahira J.J. Urinalysis: a comprehensive review. Am Fam Physician 71 (2005) 1153-1162
23. Sidaway J.E., Davidson R.G., McTaggart F., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15 (2004) 2258-2265
24. Verhulst A., D'Haese P.C., and De Broe M.E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15 (2004) 2249-2257
25. van Zyl-Smit R., Firth J.C., Duffield M., and Marais A.D. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 19 (2004) 3176-3179
26. Brewer Jr. H.B. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 92 suppl 4B (2003) 23K-29K
27. Vidt D.G., Harris S., McTaggart F., Ditmarsch M., Sager P.T., and Sorof J.M. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97 (2006) 1602-1606
28. Athyros V.G., Papageorgiou A.A., Elisaf M., Mikhailidis D.P., and GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 19 (2003) 615-617
29. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
30. Tonelli M., Moye L., Sacks F.M., Cole T., Curhan G.C., and Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 (2003) 1605-1613
31. Plosker G.L., and McTavish D. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs 50 (1995) 334-363
32. Martin P.D., Warwick M.J., Dane A.L., et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25 (2003) 2822-2835
33. Nissen S.E. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292 (2004) 1365-1367
34. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
35. Shepherd J., Hunninghake D.B., Stein E.A., et al. Safety of rosuvastatin. Am J Cardiol 94 (2004) 882-888
36. Cziraky M.J., Willey V.J., McKenney J.M., et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 97 (2006) 61C-68C
37. Goettsch W.G., Heintjes E.M., Kastelein J.J., Rabelink T.J., Johansson S., and Herings R.M. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 15 (2006) 435-443
38. McAfee A.T., Ming E.E., Seeger J.D., et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 15 (2006) 444-453
39. Zipes D.P., Zvaifler N.J., Glassock R.J., et al. Rosuvastatin: an independent analysis of risks and benefits. Med Gen Med 8 (2006) 73